Moberg is divesting OTC to fund MOB-015

14 February 2019 - Deborah Wilkes

Premium

Moberg Pharma is divesting its OTC business to two private-equity firms in a cash deal worth SEK1.43 billion (USD155 million). The Swedish company plans to focus on developing and commercialising MOB-015, its novel topical terbinafine formulation for treating nail fungus.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: